Document is current
Any future updates will be listed below
-
Authors
Takizawa, Tsubasa https://orcid.org/0000-0003-2605-7200
Takemura, Ryo https://orcid.org/0000-0002-3733-7411
Ueda, Kaname https://orcid.org/0000-0003-1967-9829
Miki, Yasuhiro https://orcid.org/0009-0005-6344-8587
Hashimoto, Chie https://orcid.org/0009-0008-0227-8993
-
Funding
Funding for this research was provided by:
Eli Lilly Japan
- License Information
-
More Information
Article History
Received: 14 November 2025
Accepted: 21 April 2026
First Online: 7 May 2026
Declarations
:
: Tsubasa Takizawa is a consultant/adviser and/or serves on an advisory board for Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Amgen K.K., Pfizer Japan Inc., AbbVie GK, and Teijin Pharma Ltd. He received speaker honoraria from Eli Lilly Japan K.K., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Amgen K.K., Kyowa Kirin Co., Ltd., Pfizer Japan Inc., and Sawai Pharmaceutical Co., Ltd., a grant from Pfizer Japan Inc., and research funding from Eli Lilly Japan K.K. and Tsumura and Co., outside the submitted work. Kaname Ueda, Yasuhiro Miki, and Chie Hashimoto are employees of Eli Lilly Japan K.K. and may own stock/stock options of Eli Lilly and Company. Ryo Takemura does not have any competing interests.
: The study was conducted per ethical principles originating from the Declaration of Helsinki and that were consistent with Good Pharmacoepidemiology Practices. All applicable Japanese laws and regulations were followed. Since this was a noninterventional, retrospective study that used anonymized patient data, ethical review and informed consent were not required per the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. Data were obtained under license from IQVIA Solutions Japan G.K. (Tokyo, Japan). Copyright IQVIA. All rights reserved.
